The Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND) for MGB Biopharma’s lead candidate MGB-BP-3, for the treatment of clostridium difficile-associated diarrhoea.
News
Antimicrobial resistance “as big a danger to humanity as climate change or warfare”
The UK has launched a five-year action plan and 20-year vision for antimicrobial resistance (AMR).
Novo Nordisk stockpiling over double usual amount ahead of Brexit
Novo Nordisk says it has planned for all future ‘no-deal’ Brexit contingencies, including doubling UK stock to 16 weeks (around four months of supply), which will be in place by the end of January.
UK university clinical trials to be monitored
Universities that do not improve on fulfilling their legal obligation to report clinical trials over the next six months could be brought in front of the House of Commons Science and Technology Committee to explain why they have failed to do so.
RCGP welcomes roll out of NHS App
NHS England has begun to roll out its NHS App to the public, in a move hailed by doctors’ leaders as “a significant and constructive step forward in using technology to support patients”.
15-year-old brain cancer patient to receive specialist radiotherapy
A 15-year-old boy with a rare brain tumour is set to begin innovative treatment at the NHS’s new Proton Beam Therapy centre, at The Christie hospital in Manchester.
NICE backs digital CBT for mildly depressed children and young people
The National Institute for Health and Care Excellence (NICE) has recommended digital cognitive behavioural therapy for use on the NHS in children and young people with mild depression.
Ozempic launched for type II diabetes in the UK
Novo Nordisk has announced that Ozempic, a new once-weekly GLP-1 (human glucagon-like peptide-1) analogue injection for the treatment of type II diabetes, is now available in the UK.
GSK completes Tesaro deal
GlaxoSmithKline has completed its acquisition of Tesaro, the oncology focused biopharmaceutical company.
Wren raises £18m to accelerate pipeline
Wren Therapeutics has announced the completion of a Series A financing round totalling £18 million.
CR UK streams £60m into tackling global cancer
Cancer Research UK has pledged to tackle global cancer challenges with £60 million funding.
Abcam and Loulou Foundation form CDKL5 deficiency disorder partnership
Abcam has announced a research collaboration with the Loulou Foundation to discover new tools to advance research for the development of therapeutics for CDKL5 Deficiency Disorder.
Superdrug to offer stricter mental health checks for Botox users
NHS England’s medical director has welcomed the introduction of stronger mental health safeguards for Superdrug’s new high street botox plan.
Orkambi’s use expanded for younger children
The European Commission has expanded the use of Orkambi to include children with cystic fibrosis aged two years to five years.
MHRA grants approval for RXC004 trial restart
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given formal approval for Redx Pharma to re-commence a Phase I/IIa trial of experimental cancer therapy RXC004.
